Humana (HUM) Q3 2025 Earnings Transcript

Humana reaffirmed full-year 2025 adjusted EPS of approximately $17 and said third-quarter medical cost trends were in line with expectations, while making about $150 million of incremental investments. Management described Bonus Year '27 Stars results as disappointing but consistent with baseline plans, but said Bonus Year '28 metrics are improving and that more than $100 million of multiyear savings should come from Genpact outsourcing and agentic AI. The company also completed the Enclara Pharmacia sale, is pursuing additional non-core asset divestitures, and expects the Villages Health acquisition to close this month.

Analysis

Humana’s setup is less about the quarter and more about the shape of the next 4-6 quarters: management is explicitly trading near-term volume for longer-duration economics. The key signal is that they are willing to throttle sales if channel/product mix starts to stress service capacity, which should improve lifetime value but mechanically caps top-line beta versus peers still chasing membership. That makes this a higher-quality, lower-volatility compounding story only if execution on retention and Stars keeps improving faster than the market discounts.

The second-order beneficiary is the provider network and outsourced services ecosystem, not Humana’s competitors. Pulling finance work to Genpact and pushing AI into call-center workflows should lower SG&A and improve claims/service throughput, but the real P&L leverage comes from fewer avoidable interactions and better retention economics; that tends to show up with a lag, so near-term consensus will underappreciate it. Conversely, the decision not to crosswalk away from concentrated contracts keeps a short-term Stars overhang alive, meaning the stock can remain range-bound until investors see evidence that FY26 pricing and FY28 metrics are converging.

The market is likely overestimating the downside from the current Stars disappointment and underestimating the upside from mix shift. If sales are genuinely coming from higher-value channels and 4+ star plans while plan-to-plan churn falls, the 2026 earnings path can inflect faster than the headline Stars issue suggests, because the company is rebuilding unit economics rather than maximizing unit count. The risk is that operational capacity proves tighter than expected and management has to sacrifice growth just as competitors exploit market disruption; that would delay the retention thesis and keep the multiple depressed through the 2026 AEP/OEP cycle.

Key Decisions for Investors

• Buy HUM on weakness into AEP/OEP volatility (next 1-3 months) with a 12-month view: the setup favors a re-rating as retention and mix improvements feed through to 2026 margin, but size modestly because Stars remains a quarterly headline risk.
• Pair trade: long HUM / short a more membership-growth-at-any-cost managed care name over the next 6-9 months; the relative winner should be the insurer with better unit economics and less need to subsidize volume.
• Sell downside puts or structure a bullish call spread in HUM expiring after the 2026 enrollment cycle if implied volatility stays elevated; the stock is likely to stay range-bound until data confirms retention gains, but the asymmetry improves if Stars progress is validated.
• Avoid chasing healthcare services/benefits vendors tied to Humana’s outsourced efficiency push unless pricing is already embedded; the incremental savings are meaningful but likely spread over years, not quarters.
• Watch for a catalyst trade after first hard evidence on 2026 pricing and retention (late Q1 to mid-2026): if management confirms stable or better margin on new sales, add aggressively; if capacity constraints force sales throttling, expect a temporary de-rate.